A phase 3 trial did not find that the efficacy of afatinib was superior to trastuzumab, and a cell experiment showed that dacomitinib maintained a high activity in HER2-amplified breast cancer lines resistant to trastuzumab and lapatinib [74,75]. Here, ERBB2 is linked to breast cancer.